VTVT Overview

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is51.33 USD with a low forecast of 40.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

vTv Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

vTv Therapeutics Inc. EPS for the last quarter amounts to -0.57 USD, increased 3.64

vTv Therapeutics Inc (VTVT) has 23 emplpoyees as of March 13 2026.

Today VTVT has the market capitalization of 132.78M USD.